A rare case of osteonecrosis of the jaw related to imatinib
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Osteonecrosis of the jaw (ONJ) is commonly described as an adverse effect of the use of bisphosphonates. A few cases of ONJ associated with tyrosine kinase inhibitors (sunitinib, imatinib) have been reported in the literature and usually they occurred in patients simultaneously treated with bisphosphonates. We report an atypical case of ONJ related only to imatinib. A 72-year-old male patient was treated with imatinib for metastases from gastrointestinal stromal tumors (GISTs). The patient developed ONJ after 22 months of imatinib only therapy. During his whole life, the patient had never been treated with bisphosphonates or radiotherapy. Microscope examination of the tissues confirmed the clinical diagnosis of diffuse osteonecrosis and showed absence of neoplastic cells. Thus, secondary localisations from GISTs were ruled out. Osteonecrosis of the lower jaw appeared 22 months after initial and exclusive therapy with imatinib. Therefore, imatinib monotherapy can induce ONJ in patients that have never been treated with bisphosphonates or radiotherapy.
Abstract
Osteonecrosis of the jaw (ONJ) is commonly described as an adverse effect of the use of bisphosphonates. A few cases of ONJ associated with tyrosine kinase inhibitors (sunitinib, imatinib) have been reported in the literature and usually they occurred in patients simultaneously treated with bisphosphonates. We report an atypical case of ONJ related only to imatinib. A 72-year-old male patient was treated with imatinib for metastases from gastrointestinal stromal tumors (GISTs). The patient developed ONJ after 22 months of imatinib only therapy. During his whole life, the patient had never been treated with bisphosphonates or radiotherapy. Microscope examination of the tissues confirmed the clinical diagnosis of diffuse osteonecrosis and showed absence of neoplastic cells. Thus, secondary localisations from GISTs were ruled out. Osteonecrosis of the lower jaw appeared 22 months after initial and exclusive therapy with imatinib. Therefore, imatinib monotherapy can induce ONJ in patients that have never been treated with bisphosphonates or radiotherapy.
참고문헌 (12)
- Dulucq S, "The pharmacogenetics of imanitib", Genome Med, 2, pp.85~ (2010)
- Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update", J Oral Maxillofac Surg, 72, pp.1938~1956 (2014)
- Lutz JC, "Mandibular metastases from an ileum stromal tumor", Rev Stomatol Chir Maxillofac, 109, pp.399~402 (2008)
- Joensuu H, "Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor", N Engl J Med, 344, pp.1052~1056 (2001)
- Yeh CN, "Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor", J Clin Oncol, 31, pp.e248~e250 (2013)
- Nicolatou-Galitis O, "Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib. A case report with clinical implications", Forum Clin Oncol, 4, pp.29~33 (2013)
- Beuselinck B, "Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases", Br J Cancer, 107, pp.1665~1671 (2012)
- Fleissig Y, "Sunitinib related osteonecrosis of jaw: a case report", Oral Surg Oral Med Oral Pathol Oral Radiol, 113, pp.e1~e3 (2012)
- Abramson RG, "Complications of targeted drug therapies for solid malignancies:manifestations and mechanisms", AJR Am J Roentgenol, 200, pp.475~483 (2013)
- Vlahovic G, "Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation", Br J Cancer, 95, pp.1013~1019 (2006)
- Litz J, "Imatinib inhibits c-Kit-induced hypoxiainducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells", Mol Cancer Ther, 5, pp.1415~1422 (2006)
- Vandyke K, "Dysregulation of bone remodeling by imatinib mesylate", Blood, 115, pp.766~774 (2010)